NP-213 is under clinical development by Novabiotics and currently in Phase II for Onychomycosis (Tinea Unguium). According to GlobalData, Phase II drugs for Onychomycosis (Tinea Unguium) have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NP-213’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NP-213 overview
NP-213 (Novexatin) is under development for the treatment of onychomycosis. NP213 is a third-generation synthetic cationic antimicrobial peptide (cAMP) administered topically as a solution form. NP213 is a cyclic arginine-based heptamer based on rational drug design technology platform. Novexatin penetrates full-thickness nail, remaining active in the nail bed, without being absorbed into the skin.
Novabiotics overview
Novabiotics is a biotechnology company that designs and develops anti-infectives for treating diseases with unmet medical needs. The company’s pipeline products include Novexatin NP213, Nylexa NM002, Lynovex NM001, Novamycin NP339, Novarifyn NP432 and Luminaderm NP108. Its Lynovex NM001 product is an orphan drug candidate for cystic fibrosis and Novexatin NP213, a novel cationic antifungal peptide, which has been formulated as a brush-on-treatment for onychomycosis. The company employs proprietary anti-infective peptide platform and antibacterial-mucolytic compounds such as Lynovex, to derive clinical stage antimicrobials. It operates in the UK and the US. Novabiotics is headquartered in Aberdeen, the UK.
For a complete picture of NP-213’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
